Clinical Trial: An Open Label Extension Study in Subjects With Fragile X Syndrome

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional




Official Title: An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subject With Fragile X Syndrome

Brief Summary: This study will enroll subjects who have completed Protocols 209FX301, 209FX302, or are currently participating in Protocol 2202 into a long-term study in which all subjects will receive active drug (arbaclofen).